Companies › medac
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Immunology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MC0518 Mesenchymal stromal cells | – | Phase 3 | Steroid-refractory Acute Graft-versus-host Disease | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04629833 | MC0518 | Phase 3 | Steroid-refractory Acute Graft-versus-host Disease | Immunology | Aug 2027 |
| NCT06075706 | MC0518 | Phase 2 | Steroid-refractory Acute Graft-versus-host Disease | Immunology | Jun 2031 |
No annotated target.
–
Doron Therapeutics UnicoCell Biomed ALK-Abelló Kolon TissueGene Inmunotek
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.